Science Explorer Back to mapMap
Discussion
Institution · VIR Biotechnology (United States)

Most cited papers from VIR Biotechnology (United States)

VIR Biotechnology (United States)

What are the most cited papers from VIR Biotechnology (United States)?

The most cited paper from VIR Biotechnology (United States) is "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1" (Daniel J. Klionsky et al., 2021), with 2,743 citations. Next come "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody" (2,164) and "Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology" (1,646).

Showing 50 of 59 papers. Every paper with more than 198 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors 2 Jan 2021 2,743
2 Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody Dora Pinto et al. · Nature Open access 18 May 2020 2,164
3 Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology Luca Piccoli et al. · Cell Open access 16 Sep 2020 1,646
4 Identification of the platelet ADP receptor targeted by antithrombotic drugs Gunther Hollopeter, Hans‐Michael Jantzen, D Vincent et al. · Nature 2001 1,433
5 Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Elisabetta Cameroni et al. · Nature Open access 23 Dec 2021 1,212
6 Antiretroviral-Drug Resistance among Patients Recently Infected with HIV Susan J. Little, Sarah Holte, Jean‐Pierre Routy et al. · New England Journal of Medicine Open access 8 Aug 2002 1,148
7 Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule Jianhua Cheng, Tong Zhou, Changdan Liu et al. · Science 25 Mar 1994 1,127
8 N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 Matthew McCallum et al. · Cell Open access 18 Mar 2021 1,027
9 Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Rita E. Chen et al. · Nature Medicine Open access 4 Mar 2021 1,018
10 An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies Laura A. VanBlargan, John M. Errico, Peter Halfmann et al. · Nature Medicine Open access 19 Jan 2022 772
11 Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies Dami A. Collier et al. · Nature Open access1,136 authors 11 Mar 2021 717
12 Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies James Μ. Binley, Terri Wrin, Bette Korber et al. · Journal of Virology Open access 12 Nov 2004 702
13 Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia Steven G. Deeks, Terri Wrin, Teri J. Liegler et al. · New England Journal of Medicine Open access 15 Feb 2001 662
14 Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity Emma C. Thomson et al. · Cell Open access 28 Jan 2021 660
15 A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 Christos J. Petropoulos, Neil T. Parkin, Kay L. Limoli et al. · Antimicrobial Agents and Chemotherapy Open access Apr 2000 653
16 Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms M. Alejandra Tortorici et al. · Science Open access 24 Sep 2020 631
17 SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape Tyler N. Starr et al. · Nature Open access 14 Jul 2021 603
18 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen et al. · Science Open access 24 Feb 2022 576
19 The foundations of immune checkpoint blockade and the ipilimumab approval decennial Alan J. Korman, Sarah C. Garrett-Thomson, Nils Carl Lønberg · Nature Reviews Drug Discovery Review 22 Dec 2021 572
20 Domains specifying thrombin–receptor interaction Thien-Khai H. Vu, Virginia I. Wheaton, David T. Hung et al. · Nature Oct 1991 556
21 Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients Evelyne T. Lennette, David J. Blackbourn, Jay A. Levy · The Lancet Sep 1996 546
22 A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Ann M. Arvin, Katja Fink, Michael Schmid et al. · Nature Open access 13 Jul 2020 543
23 Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 James Brett Case et al. · Cell Host & Microbe Open access 2 Jul 2020 489
24 SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern Matthew McCallum et al. · Science Open access Jul 2021 465
25 Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7 Bo Meng et al. · Cell Reports Open access882 authors Jun 2021 454
26 Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors Frederick M. Hecht, Robert M. Grant, Christos J. Petropoulos et al. · New England Journal of Medicine Open access 30 Jul 1998 453
27 After the pandemic: perspectives on the future trajectory of COVID-19 Amalio Telenti, Ann M. Arvin, Lawrence Corey et al. · Nature Open access 8 Jul 2021 449
28 Clinical targeting of HIV capsid protein with a long-acting small molecule John O. Link et al. · Nature Open access Jul 2020 447
29 Broad betacoronavirus neutralization by a stem helix–specific human antibody Dora Pinto et al. · Science Open access 3 Aug 2021 445
30 Tackling COVID-19 with neutralizing monoclonal antibodies Davide Corti, Lisa A. Purcell, Gyorgy Snell et al. · Cell Open access 26 May 2021 422
31 Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study Sarah J. Hallberg, Amy L. McKenzie, Paul T. Williams et al. · Diabetes Therapy Open access 7 Feb 2018 422
32 PDGF-D, a new protease-activated growth factor William J. LaRochelle, Michael Jeffers, William F. McDonald et al. · Nature Cell Biology 11 Apr 2001 418
33 Intercellular Mitochondria Transfer to Macrophages Regulates White Adipose Tissue Homeostasis and Is Impaired in Obesity Jonathan R. Brestoff et al. · Cell Metabolism Open access 4 Dec 2020 415
34 The prevalence of antiretroviral drug resistance in the United States Douglas D. Richman, Sally C. Morton, Terri Wrin et al. · AIDS 2 Jul 2004 414
35 Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA Stefan G. Sarafianos, Kalyan Kumar Das, Chris Tantillo et al. · The EMBO Journal Open access 15 Mar 2001 410
36 VISTA is an acidic pH-selective ligand for PSGL-1 Robert J. Johnston et al. · Nature 23 Oct 2019 405
37 Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence Salvador Macip, Makoto Igarashi, Fang Li et al. · The EMBO Journal Open access May 2002 378
38 Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 Aran F. Labrijn, Pascal Poignard, Aarti Raja et al. · Journal of Virology Open access 11 Sep 2003 358
39 WDFY4 is required for cross-presentation in response to viral and tumor antigens Derek J. Theisen, Jesse T. Davidson, Carlos G. Briseño et al. · Science Open access 8 Nov 2018 357
40 Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution Tyler N. Starr, Allison J. Greaney, William W. Hannon et al. · Science Open access 28 Jun 2022 349
41 Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies Florian A. Lempp et al. · Nature Open access 31 Aug 2021 329
42 Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signalling and platelet function Debbie A. Law, Francis R. DeGuzman, Patrick W. Heiser et al. · Nature Oct 1999 327
43 Broad sarbecovirus neutralization by a human monoclonal antibody M. Alejandra Tortorici et al. · Nature Open access 19 Jul 2021 320
44 Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse et al. · Science Open access 23 Dec 2021 317
45 Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. Robert Murry Scarborough, Jack W. Rose, M.A. Naughton et al. · Journal of Biological Chemistry Open access 1993 297
46 Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 Anil Kumar Gupta et al. · JAMA Open access 14 Mar 2022 295
47 Cross-neutralization of four paramyxoviruses by a human monoclonal antibody Davide Corti, Siro Bianchi, Fabrizia Vanzetta et al. · Nature 16 Aug 2013 290
48 Advances in quantitative PCR technology: 5′ nuclease assays Yolanda Lie, Christos J. Petropoulos · Current Opinion in Biotechnology Feb 1998 269
49 Imprinted antibody responses against SARS-CoV-2 Omicron sublineages Young‐Jun Park et al. · Science Open access 20 Oct 2022 267
50 The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 Andrea L. Cathcart et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 10 Mar 2021 255

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.